<DOC>
	<DOCNO>NCT00001300</DOCNO>
	<brief_summary>Randomized study . All patient must randomize treatment Arms I II within 3 month definitive surgery Regimen A . Regimen A : Surgery follow , indicate , Radiotherapy . Amputation ; limb-sparing resection follow involved-field irradiation use megavoltage equipment without electron boost . Arm I : 2-Drug Combination Chemotherapy Hematologic Toxicity Attenuation Urothelial Protection . Doxorubicin , DOX , NSC-123127 ; Ifosfamide , IFF , NSC-109724 ; Granulocyte Colony Stimulating Factor ( Amgen ) , G-CSF , NSC-614629 ; Mesna , NSC-113891 . Arm II : Observation . No adjuvant chemotherapy .</brief_summary>
	<brief_title>A Randomized Study Effect Adjuvant Chemotherapy With Doxorubicin Ifosfamide With Mesna Treatment High-Grade Adult Extremity Soft Tissue Sarcoma</brief_title>
	<detailed_description>Patients primary , high-grade soft tissue sarcoma extremity undergo treatment primary tumor either amputation limb-sparing surgery radiotherapy , randomize either observation adjuvant treatment doxorubicin ifosfamide mesna ( G-CSF ) five cycle begin post-operatively . Local recurrence , disease-free survival overall survival evaluate randomized two-arm trial .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven AR ESFT include : Classical , atypical extraosseous Ewing 's sarcoma , primitive peripheral neuroectodermal tumor , peripheral neuroepithelioma , primitive sarcoma bone , ectomesenchymoma . Confirmed presence tumorspecific infusion protein document RTPCR correspond one tumor specific peptide available vaccination . Measurable tumor . No prior current CNS metastasis . PRIOR/CONCURRENT THERAPY : Arm A patient : May enrol protocol first phase absence RT PCR documentation tumorspecific fusion protein correspond one tumorspecific peptides available vaccination . However , RT PCR documentation time tumor recurrence must occur prior administration immunotherapy . At time initial tumor diagnosis , prior cytoreductive therapy . Arm B patient : Tumor recurrence occur receive least first line cytoreductive therapy ESFT AR . No two postrecurrence salvage regimens unless peripheral CD4+T cell number great 400 cell per millimeter cubed . At least 6 week since treatment recover acute toxic effect time immunotherapy start study . No concurrent estrogen therapy immunotherapy section study . PATIENT CHARACTERISTICS : Age : 225 ( time initial diagnosis alveolar rhabdomyosarcoma ) . Weight : Greater 15 kg ( time apheresis ) . Performance status : ECOG 02 . Life expectancy : At least 8 week . Hematopoietic : ANC great 100,000/mm3 . Hemoglobin great 9.0 g/dL . Platelet count great 50,000/mm3 . Hepatic : Bilirubin le 2.0 mg/dL ( unless relate involvement tumor ) . Transaminases less 3 time normal ( unless relate involvement tumor ) . Renal : Creatinine le 1.5 mg/dL creatinine clearance great 60 mL/min . Cardiovascular : No major disorder cardiovascular system . Cardiac ejection fraction great 40 % . Pulmonary : No major disorder pulmonary system . Other : Not pregnant nursing . HIV negative . Hepatitis B C negative . No patient require daily oral corticosteroid therapy . If allergic egg , egg product , thimerosal , history GuillainBarre syndrome , ineligible receive influenza vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Adjuvant Chemotherapy</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Randomized Study</keyword>
	<keyword>Soft Tissue Sarcoma</keyword>
</DOC>